Tag: Global market

In 2024, North America was the largest revenue-generating market for Ozempic, with the United States accounting for a significant majority of its sales. The global success of this GLP-1 receptor agonist, manufactured by Novo Nordisk, is driven by various market factors, including high rates of type 2 diabetes and obesity, as well as distinct pricing structures across different regions.

As of early 2025, semaglutide, marketed under various brand names, is available in dozens of countries worldwide, with availability expanding rapidly, particularly in major markets like the US, China, and across Europe. However, its use and reimbursement policies differ significantly depending on the country and specific product formulation.